Leqembi Approval Causes A Ripple Effect For Precision In Alzheimer’s
Insights From AC Immune CEO, Andrea Pfeifer
Executive Summary
On the heels of the FDA’s full approval of Biogen and Eisai’s Leqembi, AC Immune’s CEO is hopeful that a precision medicine approach with improved diagnosis, prevention and treatment of Alzheimer’s disease is not far down the road. With 16 clinical programs, notable partnerships and wholly owned assets, AC Immune holds a strong position to help reach that destination.